Donald Paul King

US Patent:

48164046, Mar 28, 1989

Filed:

Feb 18, 1986

Appl. No.:

6/830697

Inventors:

Nicole Suciu-Foca - Cliffside Park NJ
Donald W. King - Chicago IL

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C12N 500
C07K 1504

US Classification:

43524027

Abstract:

Late differentiation antigens (LDA. sub. 1 and LDA. sub. 2) expressed by activated helper cells are described. LDA. sub. 1 and LDA. sub. 2 are membrane proteins recognized by monoclonal antibodies produced by immunizing mice with alloreactive human T cell clones with helper function. LDA. sub. 1 and LDA. sub. 2 are expressed by helper T cells. LDA. sub. 1 monoclonal antibody and LDA. sub. 2 monoclonal antibody block T cell enhancement of B cell immunoglobulin production. Thus, LDA. sub. 1 and LDA. sub. 2 are associated with helper T cell effector function. Methods of diagnosis and therepy based upon LDA. sub. 1 and LDA. sub. 2 are also described.

US Patent:

50665812, Nov 19, 1991

Filed:

Feb 5, 1987

Appl. No.:

7/011004

Inventors:

Nicole Suciu-Foca - Cliffside Park NJ
Donald W. King - Chicago IL

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07K 1506
C07K 1528
G01N 33567
G01N 33577

US Classification:

435 724

Abstract:

This invention provides a purified new differentiation antigen, designated NDA. sub. 3, associated with the growth and proliferation of activated B lymphocytes and characterized by a molecular weight of about 36,000 daltons. The invention also provides an antibody capable of specifically forming a complex with purified NDA. sub. 3. Another aspect of the invention provides a hybridoma which produces a monoclonal antibody that specifically recognizes the isolated NDA. sub. 3. The invention also pertains to a method for detecting B cells or helper T cells, each of which has a B cell growth factor receptor, which comprises contacting a sample which contains B cells or helper T cells with substances capable of forming complexes with the B cell growth factor receptors so as to form cellular complexes between the substances and the B cell growth factor receptors, and detecting such cellular complexes.

US Patent:

54057507, Apr 11, 1995

Filed:

Jun 2, 1992

Appl. No.:

7/893596

Inventors:

Nicole Suciu-Foca - Cliffside Park NJ
Donald W. King - Chicago IL

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07K 1528
G01N 33577

US Classification:

435724

Abstract:

This invention provides a purified new differentiation antigen, designated NDA4, associated with the growth and proliferation of activated B lymphocytes and characterized by a molecular weight of about 46,000 daltons. The invention also provides an antibody capable of specifically forming a complex with purified NDA4, and a hybridoma which produces a monoclonal antibody that specifically recognizes the isolated NDA4. The invention also pertains to a method for dectecting B cells or helper T cells, each of which has a B cell growth factor receptor, which comprises contacting a sample which contains B cells or helper T cells with substances capable of forming complexes with the B cell growth factor receptors so as to form cellular complexes between the substances and the B cell growth factor receptors, and detecting such cellular complexes.

US Patent:

48186899, Apr 4, 1989

Filed:

Jul 5, 1985

Appl. No.:

6/752397

Inventors:

Nicole Suciu-Foca - Cliffside Park NJ
Donald W. King - Chicago IL

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 3353

US Classification:

435 7

Abstract:

A late differentiation antigen (LDA. sub. 1) expressed by activated helper cells is described. LDA. sub. 1 is a membrane protein recognized by a monoclonal antibody produced by immunizing mice with an alloreactive human T cell clone with helper function. LDA. sub. 1 is expressed by helper T cells optionally 9 days after activation. Anti-LDA. sub. 1 monoclonal antibody blocks T cell enhancement of B-cell immunoglobulin production. Thus, LDA. sub. 1 is associated with helper T cell effector function. Methods of diagnosis and therapy based upon LDA. sub. 1 are also described.